Oakland Southfield Physicians

OSP News

FDA Approves Empagliflozin (Jardiance) for Heart Failure Regardless of Ejection Fraction

Posted: 03/01/2022

The FDA has approved an expanded heart failure indication for the SGLT2 inhibitor empagliflozin (Jardiance) that now includes heart failure with mid-range or preserved left-ventricular ejection fraction (LVEF).

The expanded indication, specifically for reducing the risk of cardiovascular death and heart failure hospitalization in adults, was widely anticipated based on the landmark results from the EMPEROR-Preserved trial. The study saw a significant 21% relative reduction in that composite endpoint over about 2 years in patients with NYHA class II-IV heart failure and an LVEF greater than 40% who received empagliflozin along with other standard care.

Click here for more information on this approval.

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.


OSP Technical Support